Moleculin Biotech Inc. announced that it has received a deficiency letter from the Nasdaq Stock Market, indicating that its common stock has not met the minimum bid price requirement of $1.00 per share for the past 30 consecutive business days. This issue pertains to Nasdaq Listing Rule 5550(a)(2). Although this deficiency does not result in immediate delisting, the company has until December 24, 2025, to regain compliance. To do so, the stock price must close at or above $1.00 for at least 10 consecutive business days. Moleculin Biotech is considering options, including a possible reverse stock split, to address the issue. If the company fails to meet this requirement by the deadline and is not granted an additional compliance period, it may face delisting, though it can appeal this decision.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.